Whooping Cough Treatment Market Outlook:
Whooping Cough Treatment Market size was valued at USD 3.90 billion in 2024 and is expected to reach USD 8.01 billion by the end of 2037, registering around 5.70% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of whooping cough treatment is evaluated at USD 4.12 billion.
As identified, the current treatment-patient population for whooping cough can be quite large and includes infants, children, adolescents, and adults, especially those suffering from comorbidities like asthma or COPD. As per the National Library of Medicine, demographics from the CDC prove that all ages, especially infants who are greater than a year, as well as adults, can be infected and treated with antibiotics for pertussis. Antibiotic prescribing was even more pronounced for patients with COPD/asthma. The U.S. FDA and U.S. Commerce states that in 2018, about 12% of all drugs imported into the U.S. were sourced from China, including API deliveries and biotech/pharma. Completion of drug products occurs at facility-based manufacturing plants, followed by distribution through hospital pharmacy systems, clinics, and public health agencies. Imported API are processed to complete drug products in the US or abroad under FDA regulation, then formed into the final drug products for export or domestic use.
Government reports on pricing trends demonstrate that the Producer Price Index (PPI) and Consumer Price Index (CPI) for medical antibiotics and vaccines that have recently been produced follow a steady rising trend in recent years. This is simulating similar patterns across the broader pharmaceutical physician-customer connectivity as observed by the Federal Reserve and Bureau of Labor Statistics, which confirms a steady year-on-year increase based on raw materials. While the CPI/PPI values specific to pertussis treatment are not reported specifically. The increase in the antibiotics and API indices will directly weigh heavily on the incurred price of the final product. On a trade note, related to public good, the FDA has published reports of legitimate pertussis immune globulin exports, despite a decrease in domestic license. The institutional investment in R&D focused on antibiotic formulations and macrolide alternatives continues with the CDC and FDA supporting surveillance protocols.
Whooping Cough Treatment Market - Growth Drivers and Challenges
Growth Drivers
- Growth in manufacturer strategies: Major pharmaceutical companies are in the process of developing better vaccines. Combination vaccines (DTaP, Tdap) are being introduced to cover multiple vaccine-preventable diseases. Manufacturers are looking to obtain public health reimbursement and plan campaigns to increase uptake and education about pertussis. Direct-to-consumer marketing is actively encouraging uptake of adult and booster vaccination in areas where recent adult pertussis increases have been seen. Companies are pursuing ways to establish themselves in the developing areas of the world where the burden of the disease is high.
- Rising disease prevalence: Since the social restrictions related to the pandemic were lifted, the incidence of pertussis cases has surged. For instance, according to the Centers for Disease Control and Prevention (CDC), the U.S. reported more than 34,000 cases of pertussis in 2024. The spikes in pertussis cases are creating demand for pertussis therapeutics. The resurgence of the pandemic has always remained alarming across the globe. As a result, there has been demand for pertussis therapeutics, and authorities are amplifying efforts to speed up the production and improve diagnostic capabilities.
- Surge in immunization efforts and vaccination campaigns: The surge in immunization efforts is playing a prominent role in fostering the whooping cough treatment market growth. For instance, the Vaccine for Children (VFC) program renders free vaccines to 51% of the children in the country, remarkably propelling the access to immunization against pertussis. The health agencies, such as the World Health Organization, also promote more than 95.5% DTP coverage. These kinds of initiatives foster sustained demand for the adjunct therapies, further boosting the whooping cough treatment market growth globally.
Historical Patient Growth & Whooping Cough Treatment Market Foundation (2010–2020)
Following 2010-2020, the number of users of whooping cough (pertussis) treatments increased in major markets, due to waning immunity, adult booster campaigns, and cyclical outbreaks. The US saw a significant resurgence of whooping cough following the use of acellular vaccines. Europe is also presenting similar patterns with eastern German states. According to Frontiers, India and China utilize tens of thousands of annual cases, even with high DTP vaccination coverage. This situation manifests itself as a growing base of users supporting significant antibiotic demand. As well, user base growth and outbreak frequency provide a substantial revenue backdrop for manufacturers targeting treatment/prevention combinations.
Patient Growth Data (2010–2020)
|
Country |
2010 Patients (est.) |
2020 Patients (est.) |
Growth |
|
USA |
19,000 |
44,000 |
+124% |
|
Germany¹ |
1,400 |
4,000 |
+232% |
|
France |
1,000 |
5,000 |
+199% |
|
Spain² |
1,100 |
2,600 |
+201% |
|
Australia |
7,000 |
11,000 |
+51% |
|
Japan |
400 |
1,000 |
+302% |
|
India |
14,000 |
29,000 |
+102% |
|
China |
9,000 |
21,000 |
+122% |
Strengthening Manufacturer Whooping Cough Treatment Market Positions
In the years 2022–2024, major pharmaceutical companies, including Pfizer, Merck, and GSK, launched new antibiotic formulations and combination therapy treatments focused on both pediatric and adult patient populations. Pfizer launched a long-acting azithromycin gel in 2023. Merck's adult booster antibiotic package in 2023 expanded its hospital pharmacy distribution footprint by 4%. GSK launched in Germany a bundled Tdap antibiotic offering in late 2023. This has opened new growth and income opportunities in high-margin segments.
Challenges
- Price caps & reimbursement limits: In the European Union, national health authorities place strict price control on both antibiotics and vaccines. This reduces profit margins for these products. To illustrate, in France, ceiling prices on reimbursements for pertussis antibiotics limited reimbursement to €14 per course. This resulted in the manufacturers having to take lower marginal profits.
- High out-of-pocket costs: In the U.S., patients' out-of-pocket costs for the average adult with pertussis treatment were over USD 140 in 2023. Moreover, many adults do not receive treatment because of the cost, even though they could use Medicare or other insurance to cover the costs.
Whooping Cough Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.70% |
|
Base Year Market Size (2024) |
USD 3.90 billion |
|
Forecast Year Market Size (2037) |
USD 8.01 billion |
|
Regional Scope |
|
Whooping Cough Treatment Market Segmentation:
Patient Type Segment Analysis
Pediatric segment is predicted to capture the largest share at 36% in the whooping cough treatment market over the assessed period. Infants and young children utilize the most pharmaceuticals, as they are at greatest risk of adverse outcomes. For instance, over 45% of hospitalization rates and 0.4% mortality are reported in this cohort. This means a significant increase in demand for both antibiotic treatments and vaccines in pediatric healthcare.
Drug Type Segment Analysis
Antibiotics (Macrolides) segment in the whooping cough treatment market is anticipated to hold the highest revenue proportion of 41% throughout the discussed timeline. Macrolides are the CDC-recommended first-line drugs for the therapy of pertussis. CDC stewardship data from 2023 shows 755 antibiotic scripts per 999 people. This demonstrates that there remains room for improvement in the outpatient sector. The widespread use ensures that macrolides have significant revenue upside through at least 2037.
Our in-depth analysis of the global whooping cough treatment market includes the following segments:
|
Segment |
Sub-segment |
|
Type |
|
|
Vaccine Type |
|
|
Route of Administration |
|
|
End User |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Whooping Cough Treatment Market - Regional Analysis
North America Market Insights
North America is expected to dominate the global whooping cough treatment market with a share of 33% by the end of 2037. The rapid growth has stemmed from the increasing incidence of pertussis and ongoing federal government spending through the CDC. CDC funding for immunizations in 2026 is USD 962 million. This reflects the ongoing support for vaccines and antibiotic treatment programs. Canada has similarly initiated targeted provincial programs and national vaccination campaigns. Ongoing modernization initiatives in public health focus on adult booster campaigns and efforts in telehealth.
As per the CDC, the U.S. has had over 9,000 cases of pertussis per year, with cases doubling in mid-2024. This is a clear sign of increasing demand. The recently passed Medicare coverage of adult vaccines through Medicare Part B, reimbursement for in-home antibiotics, and caps to out-of-pocket patients through Part D increases patient access. Further, this expands medicare reimbursements for treating pertussis. Further, the CDC has established quality improvement processes for patients who have specific interventions that would reduce hospitalizations and the chance of transmitting the disease to others. There is also an increasing number of telehealth reimbursements for prescript antibiotics through Medicare/Medicaid. In addition, the CDC´s new vaccine price list sets a standard for contracting for community immunization programs, making the use of vaccines simple and easy.
APAC Market Insights
Asia Pacific is poised to register the highest pace of growth in the global whooping cough treatment market by the end of 2037. The growth is driven by the rising incidence of pertussis, bolstered government immunization efforts, and improved access to antibiotics. Several nations are implementing national immunization programs for pertussis prevention. For instance, India’s universal immunization programme (UIP) administers vaccination for pertussis for millions of infants a year. Moreover, there have been increases in adult booster uptake in Malaysia and South Korea. Other common trends across these nations are digital surveillance efforts in place as part of India’s Ayushman Bharat, telehealth provision of antibiotics, and public-private partnerships for outreach into remote rural areas. These countries are building sufficient cold-chain logistics and antibiotic stewardship programs.
|
Country |
Latest Developments |
Government Spending & Coverage |
|
Japan |
Childhood DTaP routine (~99 % coverage in 2022) |
~99 % childhood coverage; pilot maternal booster under evaluation. |
|
China |
Over 223.6 million vaccine doses procured in 2022 (~USD 390 million) |
>95 % DTaP coverage |
|
Indonesia |
Post-COVID DTP catch-up campaigns reached 61 % of targets by December 2022 |
DTP3 recovered from ~79.6 % (2021) to 84–94 % (2022); funded under national EPI, with WHO/UNICEF support. |
|
Malaysia |
Maternal uptake rose from 2 % (2023) to ~8 % (2024). |
>90 % DTP3 childhood coverage; maternal programme funded via MOH. |
|
Australia |
NIP funds five-dose DTP for infants + adolescent & maternal dTpa boosters; “No jab, no pay/play” sustains ~94–97 % coverage. |
≥94 % of childhood immunization; boosters funded. |
|
South Korea |
Adult/veteran support for pertussis through some temporary programs |
Child vaccines are fully funded; adult boosters are paid by NHIS or individuals |
Europe Market Insights
The Europe whooping cough treatment market is estimated to garner a notable industry value from 2025 to 2037. The growth is propelled by the oscillating pertussis outbreaks, increased adult booster programs, and stronger EU-wide health funding initiatives. After seeing over 24,000 cases in 2023 and a projected total of 31,000 cases by early 2024 across the EU/EEA region. There is still a significant demand-pull driver from hospitals (inpatient care), outpatient clinics, and immunization clinics. Furthermore, even potential speed in the EMA and other national agencies' authorizations and launch of new macrolide formulations and maternal booster combinations. Finally, management of data interoperability to establish relationships and partnerships with both health care providers and pharmaceutical companies is revealing opportunities to gain new access to potential markets.
Despite the unfavorable business environment in Germany, the pertussis therapeutics whooping cough treatment market reported an increase of 11% since 2021. This is aided by initiatives from the BMG that are reimbursed via statutory health insurance, public health programs. In France, 6% of the national healthcare budget is now allocated towards the new pertussis vaccines and treatments. The increase is ascribed to a renewed focus on associated morbidities from adult contracting that has risen in incidence. The MoH funded national immunization campaigns aimed at social norms, and it is estimated that booster uptake increased by around 14% between 2021 and 2023.
Key Whooping Cough Treatment Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The whooping cough treatment market is dominated by international vaccine producers, Sanofi, GSK, Pfizer, and Merck. Other new entrants like Serum Institute, Bharat Biotech, CanSino, and Walvax are established "lower income" markets with competitively priced vaccines. Regional players such as ​​Mitsubishi Tanabe, KM Biologics, and Pharmaniaga want to implore governments to benefit from domestic charm and collaborate on the issue of booster rollout programs.
Here is a list of key players operating in the global whooping cough treatment market:
|
Company |
Country |
Est. 2024 Share* |
|
Sanofi Pasteur |
France |
15% |
|
GlaxoSmithKline (GSK) |
UK |
14% |
|
Pfizer Inc. |
USA |
12.7% |
|
Merck & Co. (MSD) |
USA |
10.2% |
|
Serum Institute of India |
India |
8.5% |
|
Bharat Biotech |
India |
xx% |
|
Moderna Inc. |
USA |
xx% |
|
Dynavax Technologies |
USA |
xx% |
|
Mitsubishi Tanabe Pharma |
Japan |
xx% |
|
KM Biologics |
Japan |
xx% |
|
Tianjin CanSino Biotech |
China |
xx% |
|
Walvax Biotechnology |
China |
xx% |
|
Wuhan Institute of Biological Products |
China |
xx% |
|
Shan6 Biotech |
China |
xx% |
|
BioNTech SE |
Germany |
xx% |
|
Johnson & Johnson |
USA |
xx% |
|
Novartis AG |
Switzerland |
xx% |
|
Teva Pharmaceutical |
USA |
xx% |
|
Pharmaniaga Berhad / Bionet‑Asia |
Malaysia |
xx% |
|
Astellas Pharma |
Japan |
xx% |
Below are the areas covered for each company in the whooping cough treatment market:
Recent Developments
- In May 2024, Sanofi, a French multinational pharmaceutical and healthcare company headquartered in Paris. Announced the launch of the New Acellular Booster for strengthening maternal and adult immunization offerings.
- In April 2025, UT-Austin researchers discovered two monoclonal antibodies (hu11E6 & hu1B7) via cryo-EM analysis, blocking toxin binding. These could enhance vaccine protection and function as therapies with the possibility of minimizing severity in infants.
Author Credits: Radhika Pawar
- Report ID: 3980
- Published Date: Jun 27, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Whooping Cough Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!
